Table 1.
Patient characteristics for glioblastoma and IDHwt astrocytoma with pTERTmut
| Glioblastoma WHO°IV | IDHwt astrocytomas with pTERTmut | Total | p-value | |
|---|---|---|---|---|
| Overall, n (%) | 224 (80%) | 57 (20%) | 281 | |
| Age, years | ||||
| < 18 | 1 (0%) | 0 | 1 (0%) | 0.695 |
| 18–35 | 11 (5%) | 0 | 11 (4%) | |
| 36–50 | 34 (15%) | 16 (28%) | 50 (18%) | |
| 51–65 | 101 (45%) | 22 (39%) | 123 (44%) | |
| > 65 | 77 (34%) | 19 (33%) | 96 (34%) | |
| Gender | ||||
| Female | 80 (36%) | 23 (40%) | 103 (37%) | 0.518 |
| Male | 144 (64%) | 34 (60%) | 178 (63%) | |
| KPS, % | ||||
| < 90 | 127 (57%) | 23 (40%) | 150 (53%) | *0.027 |
| 90–100 | 97 (43%) | 34 (60%) | 131 (47%) | |
| Histopathology | ||||
| Diffuse AST WHO°II | 0 | 18 (32%) | 18 (6%) | |
| Anaplastic AST WHO°III | 0 | 38 (67%) | 38 (14%) | |
| Gemistocytic AST WHO°II | 0 | 1 (2%) | 1 (0%) | |
| GBM WHO°IV | 224 (100%) | 0 | 224 (80%) | |
| Methylated CpG sites | ||||
| 0–8 | 99 (44%) | 21 (37%) | 120 (43%) | 0.527 |
| 9–16 | 40 (18%) | 13 (23%) | 53 (19%) | |
| 17–25 | 85 (38%) | 23 (40%) | 108 (38%) | |
| First-line therapy | ||||
| Chemotherapy | *0.001 | |||
| TMZ | 7 (3%) | 16 (28%) | 23 (8%) | |
| PC | 0 | 2 (4%) | 2 (1%) | |
| Radiotherapy | 0 | 10 (18%) | 10 (4%) | *0.001 |
| Radiochemotherapy | 216 (96%) | 15 (26%) | 231 (82%) | *0.001 |
| Brachytherapy | 1 (0%) | 4 (7%) | 6 (2%) | *0.001 |
| Wait-and-scan | 0 | 10 (18%) | 10 (4%) | *0.001 |
Characteristics are given for patients with glioblastoma, IDH-wildtype, WHO grade IV (n = 224) and IDHwt astrocytoma with pTERTmut, WHO grade II and III (n = 57); and are summarized for all patients (total; n = 281)
CpG: cytosine-guanine dinucleotide, IDHwt: isocitrate dehydrogenase 1/2 wildtype, KPS: Karnofsky performance score, MGMT: O6-methylguanine-DNA methyltransferase promotor, PC: procarbazine, lomustine, TMZ: temozolomide, TERT: telomerase reverse transcriptase promotor, pTERTmut: TERT promotor mutation, TMZ: temozolomide
Asterisks indicate *p ≤ 0.05